The Global Rickets Treatment Market to 2023; Led by F. Hoffmann-La Roche, Merck, Novartis, Pfizer, and Sanofi

DUBLIN, May 13, 2019 /PRNewswire/ -- The "Global Rickets Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The rickets treatment market will register a CAGR of nearly 6% by 2023.

The growing awareness about vitamin D deficiency is one of the key factors expected to trigger market growth in the upcoming years.

Several programs are being initiated for creating public awareness about the health issues associated with vitamin D deficiency including rickets. Such rising awareness programs are further expected to boost the global rickets treatment market growth during the forecast period.

Growing awareness about vitamin D deficiency

The increasing number of awareness programs are leading to the increasing diagnosis of the conditions caused by the deficiency of vitamin D, which, in turn, leading to the increasing use of supplements and drugs for the treatment.

Availability of substitute treatment options

Alternative therapies have a higher perceived value than the drugs, thereby the availability of substitute treatment options acts as a challenge to the growth of the global rickets treatment market during the forecast period.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. The advent of biologics is encouraging companies to develop biological therapies, especially for the treatment of rare diseases.

This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY TYPE

• Comparison by type
• Vitamin D-related rickets - Market size and forecast 2018-2023
• Minerals-related rickets - Market size and forecast 2018-2023
• Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• RoW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi

For more information about this report visit https://www.researchandmarkets.com/r/c0e86j

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-global-rickets-treatment-market-to-2023-led-by-f-hoffmann-la-roche-merck-novartis-pfizer-and-sanofi-300848248.html

SOURCE Research and Markets